GS Group contributed to a series B round that pushed messenger RNA therapeutics and vaccine developer RVAC Medicines' overall funding to $140m.

Corporate-backed medical imaging technology producer Lunit is preparing to float in South Korea while cancer drug developer Pheast secured $76m from investors including Alexandria Venture Investments.

Massachusetts Mutual Life's venture capital arm has formed a fourth fund, which will concentrate on European and Asia-Pacific investments.

CVS Health joined returning backers that could include SoftBank Vision Fund 2, MassMutual Ventures, Jianke and Aviva in a round valuing the digital care service at $1.3bn.

Yangtze River Pharmaceutical Group led Binhui Biopharm's $47m series B-plus round while Sigfox has been snapped up by UnaBiz for under $30m after raising over $300m.

The Sinopharm-backed laboratory animal model developer floated on Shanghai Stock Exchange’s Star Market two years after its last equity funding.

Web3 security software producer Certik received $60m from investors including SoftBank Vision Fund 2 while corporate-backed automation technology provider Vicarious is being bought after raising over $250m.

The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

The small molecule drug developer, co-founded by a UCLA associate professor, has completed its series B round.

SK Hynix, Marvell and M12 helped data centre technology producer D-Matrix pull in $44m while health insurance provider SafetyWing raised $35m from investors including Digital Garage and CreditEase.